“New clinical experience with 9-delta-tetrahydocannabinol (THC) and cannabidiol (CBD) oromucosal spray (Sativex®)…
A randomized, placebo controlled long-term follow-up clinical trial with THC:CBD spray versus placebo demonstrated that it was not associated with cognitive decline, depression or significant mood changes…
THC:CBD oromucosal spray did not adversely influence standard driving ability in patients with moderate to severe MS spasticity…
Findings to date reinforce the efficacy and safety observed in Phase III clinical trials…
Importantly, no additional safety concerns were identified…
Thus, these new data support a positive benefit-risk relationship for THC:CBD oromucosal spray during longer-term use.”